Navigation Links
TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
Date:3/26/2008

f acute migraine.

-- Preclinical data were published in the October 17, 2007, issue of the

Journal of Neuroscience demonstrating that tezampanel may be effective

in reversing or preventing muscle spasticity and rigidity of spinal

ischemia. TorreyPines plans to initiate a Phase II clinical trial of

tezampanel for the treatment of muscle spasticity and rigidity

secondary to spinal cord trauma during the second half of 2008. This

will be the company's first clinical trial of tezampanel in a non-pain

indication.

-- TorreyPines initiated a Phase I maximum tolerated dose trial evaluating

NGX426, the oral prodrug of tezampanel. Dosing up to 150 mg has been

completed, and the study will continue to dose until either the maximum

tolerated dose is reached or up to a maximum of 210 mg. This clinical

trial is expected to be completed in the first half of 2008.

TorreyPines reported pharmacokinetic data from this clinical trial

showing that the area under the curve (AUC), which represents the total

amount of drug absorbed by the body, of a single, 80 mg, oral dose of

NGX426 is comparable to the AUC of a single, 40 mg, subcutaneous dose

of tezampanel.

-- A multiple dose Phase I clinical trial evaluating NGX267 was completed,

marking the third Phase I trial that demonstrated NGX267 is safe and

well tolerated. This multiple dose trial confirmed data from a

previous study in which statistically significant increases in salivary

flow were detected. TorreyPines initiated a Phase II clinical trial in

xerostomia, or dry mouth, secondary to Sjogren's syndrome in

March 2008.

Financial Results

Revenue for the three-month period ended December 31, 2007, was $2.5 million, compared to revenue of $2.5 million for the same period in 2006. Operating expenses for
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
2. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
3. TorreyPines Therapeutics Reports Third Quarter 2007 Results
4. TorreyPines Therapeutics to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
5. TorreyPines Therapeutics to Present at ThinkEquitys ThinkClinic Conference
6. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
7. TorreyPines Therapeutics to Present at ThinkEquitys G5 Conference
8. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
9. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
10. Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award
11. Cell Therapeutics, Inc. (CTI) Invest Northwest Presentation to be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Calif. (PRWEB) November 20, 2014 ... nonprofit, public policy research organization representing leading California ... firms, and PwC US today released ... in life sciences industry growth. The trend shows ... The 2015 California Biomedical Industry Report ...
(Date:11/21/2014)... Arkansas (PRWEB) November 20, 2014 ... Pinnacle Ozone Solutions, LLC (Pinnacle), and PCI, Inc., ... announced that they have been selected to provide ... of Fayetteville, Arkansas Paul R. Noland Wastewater Treatment. ... BlueInGreen’s patented HyDOZ® gas dissolution technology, ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... and in-depth research report on the transformer market. ... classification, application, and industry chain structure as well ... market analysis, including China’s domestic market as well ... economic situation analysis. The report also covers information ...
(Date:11/21/2014)... SAN DIEGO , Nov. 20, 2014  Cytori Therapeutics ... Marc Hedrick , M.D. will present live at VirtualInvestorConferences.com ... 4, 2014 TIME:    11:15 am PT / 2:15 ... this URL into your browser,s address bar: http://bit.ly/1B2KGaL ... time and receive event updates. This will ...
Breaking Biology Technology:California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4City of Fayetteville Leads Nation with Innovative Ozone Technology 2City of Fayetteville Leads Nation with Innovative Ozone Technology 3City of Fayetteville Leads Nation with Innovative Ozone Technology 4International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 2Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 3Cytori Therapeutics to Provide Corporate Update and Investor Presentation on December 4 through a Live, Interactive Webcast 4
... Inc. (Nasdaq: NVAX ) today announced that it ... press release to be issued after 8:00 a.m. Eastern Time ... investor conference call to discuss its financial results at 10:00 ... will be hosted by Novavax President and Chief Executive Officer ...
... May 4 The Arcas Group, a ... Stefan Terwindt, MBA as Executive Vice President. He will ... Terwindt previously served as President of Imedex, Inc."Stefan is ... and skills to our company," said Founder and President ...
... & Company, LLC, a Boston-based life science investment bank, ... has joined the firm as senior advisor. In ... on internal and client-related activities including private equity placements ... focus on medical device transactions. "We are thrilled ...
Cached Biology Technology:Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call 2The Arcas Group Appoints Executive Vice President 2Venture Capital Veteran John Brooks Joins Life Science Investment Bank Johnston Blakely & Company 2
(Date:11/4/2014)... 2014) – A majority of Madagascar,s 101 species of ... serious consequences for the rainforests they call home. A ... impacts lemurs can have on rainforest tree populations, which ... have on the region,s rich biodiversity. , A large ... by lemurs. Lemurs in turn disperse the seeds ...
(Date:11/3/2014)... Center study published in this month,s ... the activity of a recently discovered communication molecule of ... has been known to limit inflammation and the current ... IL-37 inhibits the ability of the immune system to ... that underlies IL-37,s effect on the immune system now ...
(Date:11/2/2014)... In this month,s issue of Physics World , ... bridging the "valley of death" to take their innovations ... argues that the gruelling challenge facing all start-up companies ... harder for physicists because of two main factors: physics-based ... and they often turn out to be a lot ...
Breaking Biology News(10 mins):Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3PNAS: From HIV to cancer, IL-37 regulates immune system 2The 'valley of death' facing physics start-ups 2
... developed at the Hebrew University of Jerusalem that is ... led to approval by the U.S. Food and Drug ... cardiac surgery patients. The product is the ... biodegradable polymers for the prevention of post-surgical adhesions. SyntheMed ...
... available in German . , Helsinki/Leipzig. ... trading, will only be successful if they are coherently ... issues, says a report published today by the Partnership ... from seven of the biggest European environmental research institutes. ...
... Both plant and human diseases that can travel ... more rapidly than has been understood, according to a ... only for some human diseases but also a new ... done by scientists at Oregon State University and other ...
Cached Biology News:Hebrew University professor's work leads to FDA approval for product 2Climate change aims need to be better integrated 2New wheat disease could spread faster than expected 2New wheat disease could spread faster than expected 3
... OPTIMA is a fully automated microplate ... science labs in academia and industry. ... principles: Fluorescence Intensity including ... Fluorescence including DELFIATM High-Performance ...
... dispensers save space and organize ... and other garb. They are ... for small parts used in ... acrylic. Open-slot design for easy ...
... The MSD Security ... integrated GC/MS software application ... processing, quantification, library searching ... the aspects of data ...
... for genome-wide microRNA expression profiling and ... Paraflo microfluidic on-chip synthesis platform. These ... our comprehensive microRNA Expression Profiling Service. ... Mammals microRNA Microarray contains all known ...
Biology Products: